Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) registered a 21.26% increase, still its new closing price is 198.81% up from the company’s 1 year high of 6.97.It posted 17.84% gains in previous 5 sessions and is now the subject of 4 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 4 stock analysts following this company have an average price target at $2.00, with individual PT in the $2.00-$2.00 range. The shares moved at $2.51, implying that brokerage firms see shares losing about -57.24% in twelve months time.
Infinity Pharmaceuticals, Inc. (INFI) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 85.93% rise year to date. A 10% Owner at Infinity Pharmaceuticals, Inc. (INFI) acquired shares in a transaction closed on Tuesday January 03, 2017. BIOTECHNOLOGY VALUE FUND L P bought 4,379 shares in the company at $1.34 each and collected $5,001 in proceeds. BIOTECHNOLOGY VALUE FUND L P now owns 6,668,809 shares in the company after this transaction. A 10% Owner in the company, BIOTECHNOLOGY VALUE FUND L P, disclosed a transaction on Friday December 30, 2016 that ended up paying $994,001 from the purchase of 742,401 shares at $1.34 per share.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Upcoming Results on Tap
Infinity Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.24 in that period. Sales during the quarter are predicted to arrive at $58.8 million.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.39. The mean forecast was for $7.27 million and $-0.85 a share, respectively. One quarter earlier, revenue for the stock was at $9.47 million, with earnings at $-0.40/share.
Infinity Pharmaceuticals, Inc. (INFI) Brokerage Update
Infinity Pharmaceuticals, Inc. (INFI) is in Wells Fargo’s research list so their analyst rating change is noteworthy. These shares were downgraded to Market Perform from Outperform by Wells Fargo, according to news reported on Wednesday June 15, 2016.Another important research note was issued by Morgan Stanley on Wednesday June 15, 2016.The firm downgraded INFI to Equal-Weight from Overweight. Over the last six months and over the last three months, the shares of Infinity Pharmaceuticals, Inc. (INFI), have changed 51.20% and 107.44%, respectively.